United States  

CytoDyn says coronavirus patients treated with leronlimab show initial improvements after three days

Proactive Investors Thursday, 2 April 2020
CytoDyn Inc (OTCQB:CYDY) announced Thursday that eight severe coronavirus (COVID-19) patients being treated with its drug leronlimab have shown a significant improvement after three days in several important biologic markers.  Initial patient test data has shown improvement in cytokines — proteins released by the immune system that can cause inflammation in high quantities  — and a more normal ratio of helper T cells to killer T cells in the immune system, known as the CD4/CD8 ratio. Leronlimab has been administered to 10 severely ill coronavirus patients in the New York City area under an emergency Investigational New Drug application granted by the US Food & Drug Administration (FDA). READ: CytoDyn files second clinical trial protocol to treat severely ill coronavirus patients with lernlimab CytoDyn is also enrolling patients in a Phase 2 trial for coronavirus patients with mild-to-moderate indications and a Phase 2b/3 trial for patients who are critically ill. Bruce Patterson, the CEO of CytoDyn’s diagnostic partner and advisor IncellDX, is impressed with the results so far. “We are very pleased with our most recent laboratory data for patients treated with leronlimab for COVID-19 infection,” Patterson said in a statement. “We continue to see increases in the profoundly decreased CD8 T-lymphocyte percentages by day three, normalization of CD4/CD8 ratios and resolving cytokine production including reduced IL-6 correlating with patient improvement. The current data suggests a trend toward the restoration of immune function and mitigation of the cytokine storm. This is consistent with prior laboratory results in the first four patients treated for COVID-19 with leronlimab.” Seeing leronlimab’s initial success, CEO Nader Pourhassan and his team are also examining how best to distribute the drug across the country. “As leronlimab continues to provide hope for many patients, our management team is focused to ensure we can distribute the drug across the country in a timely fashion,” Pourhassan said. “These results, although anecdotal, appear to be very promising.” In addition to its use as a potential coronavirus treatment, leronlimab has other therapeutic indications as a treatment for HIV and certain breast cancers. Contact Andrew Kessel at [email protected]  Follow him on Twitter @andrew_kessel
0
shares
ShareTweetSavePostSend
 
Video Credit: TomoNews US - Published
News video: COVID-19 can survive on medical masks for seven days

COVID-19 can survive on medical masks for seven days 01:23

HONG KONG — New research shows SARS-CoV-2 can survive on the outer layer of a surgical mask for seven days. New research published in medRxive by medical specialists in Hong Kong shows how long SARS-CoV-2 can survive on different surfaces and in different environments. The researchers...

You Might Like


Related videos from verified sources

Researchers ID Even More Symptoms Linked To Novel Coronavirus COVID-19 [Video]

Researchers ID Even More Symptoms Linked To Novel Coronavirus COVID-19

The US Centers for Disease Control and Prevention added six new symptoms to its list for the novel coronavirus COVID-19 last week. They include chills, repeated shaking with chills, muscle pain,..

Credit: Wochit     Duration: 00:40Published
Calls to one St. Louis women’s shelter increase 44 percent [Video]

Calls to one St. Louis women’s shelter increase 44 percent

There is a lot of talk about being safe at home right now, but one St. Louis women’s shelter wants everyone to understand not everyone can be safe at home.

Credit: KTVI     Duration: 02:17Published
With graduations being canceled or postponed, Missouri parents drop-off gifts to over 300 seniors [Video]

With graduations being canceled or postponed, Missouri parents drop-off gifts to over 300 seniors

Graduating high school is a moment every senior works towards. But due to the COVID-19 pandemic many may not have the chance to walk across the stage.

Credit: KTVI     Duration: 02:00Published

Related news from verified sources

CytoDyn enrolls two patients in Phase 2 coronavirus of leronlimab; 15 severely ill patients treated separately so far

CytoDyn Inc (OTCQB:CYDY) announced Monday that the company has enrolled and begun treating the first two patients in its Phase 2 trial of leronlimab for people...
Proactive Investors

CytoDyn enrolls two patients in Phase 2 coronavirus trial of leronlimab; 15 severely ill patients treated separately so far

CytoDyn Inc (OTCQB:CYDY) announced Monday that the company has enrolled and begun treating the first two patients in its Phase 2 trial of leronlimab for people...
Proactive Investors

CytoDyn requests initial meeting with FDA for Breakthrough Therapy status for leronlimab in treating cancer

CytoDyn Inc (OTCQB:CYDY), a late-stage biotechnology company, revealed Friday that it has filed a request with the US Food and Drug Administration (FDA), for a...
Proactive Investors